Recursion
Biopharma Companies Continue Layoffs: Novartis, Recursion, and Kronos Reduce Staff Amid Industry Restructuring
Biopharma layoffs, Novartis restructuring, Recursion, Kronos, pharmaceutical industry, workforce reduction, cost-cutting measures
Recursion’s Phase 2 Trial for Cerebral Cavernous Malformation Shows Limited Efficacy Despite Meeting Safety Goals
Recursion Pharmaceuticals, Phase 2 trial, cerebral cavernous malformation (CCM), REC-994, safety and tolerability, efficacy data, FDA meeting
Recursion Pharmaceuticals’ AI-Driven Drug Development Strategy Fails to Impress Investors
Recursion Pharmaceuticals, AI, drug development, investors, biotech, pharmaceuticals
Exscientia Merges with Recursion to Form AI-Driven Drug Discovery Leader
Exscientia, Recursion, AI drug discovery, merger, precision chemistry, small molecule synthesis, biotech consolidation